Our mission is to develop a portfolio of cell therapy products that leverages the body’s natural ability to heal and fight disease.
For every therapy, we will ask basic scientific questions, such as:
What is the ‘active ingredient’?
For NeoStem, PCT’s processing and purification experience allows the targeting of cell types that can yield an essentially homogenous, enriched cell population that can achieve better results than a less pure, more heterogeneous population. We favor source material that can be isolated and enriched for the active cells in as close to their natural environment as possible. For some disease conditions we will favor autologous cell therapies and for others allogeneic. We will let the disease state versus our manufacturing acumen dictate what is best suited to the condition.
What is the biological mechanism of action?
We seek to develop products where we have a highly defined biological mechanism of action that is well established and validated with fundamental research. In defining such, we will work to understand the limits of biology and understand the correct biologically active dose (the biologic threshold dose) that accounts for cell variability across patients.
What is the biological threshold dose?
We seek to establish the biological threshold dose (i.e. the number of cells) below which the desired clinical result is not achieved so that we can establish standardization of methods for delivery of our therapeutics.
What is the expected clinical outcome?
We seek therapeutics with clinically significant outcomes that improve and extend life for patients.
The end result of these efforts is an approach to cell therapy development that is similar to traditional drug development. We will strive to deliver not just a product that works, but one that is consistent with basic and clinical science and conforms to traditional standards of drug development.